Reverse transcription polymerase chain reaction

COVID-19 Detection Kits Market Size To Reach $4.63 Billion By 2027, To Be Driven By Constant Growth in Delivery of Molecular Test Kits | Million Insights

Retrieved on: 
Monday, March 8, 2021

What are the Driving Factors for the COVID-19 Detection Kits Market?

Key Points: 
  • What are the Driving Factors for the COVID-19 Detection Kits Market?
  • Consequently, the kits for RT-PCR centered molecular analyze are observing a massive augmentation in demand, through the world.
  • The constant growth in the delivery of the molecular test kits describes the towering demand for the COVID-19 detection kits
    Please click here to get the sample pdf and find more details on "COVID-19 Detection Kits Market"Report 2027.
  • Browse 150 page research report with TOC on "Global COVID-19 Detection Kits Market" at: https://www.millioninsights.com/industry-reports/global-covid-19-detecti...
    Million Insights segmented the global COVID-19 detection kits market based on End Use, Mode, Sample Type, Product, and Region:
    COVID-19 Detection Kits Products Outlook (Revenue, USD Million, 2020 - 2027)
    COVID-19 Detection Kits Sample Type Outlook (Revenue, USD Million, 2020 - 2027)

Adaptive Biotechnologies Announces FDA Emergency Use Authorization for T-Detect™ COVID to Confirm Recent or Prior COVID-19 Infection

Retrieved on: 
Friday, March 5, 2021

People who have been unsure about a prior infection will now have another way to know if they had the virus, said Chad Robins, chief executive officer of Adaptive Biotechnologies.

Key Points: 
  • People who have been unsure about a prior infection will now have another way to know if they had the virus, said Chad Robins, chief executive officer of Adaptive Biotechnologies.
  • The authorization of T-Detect COVID represents a true breakthrough for patients and a pivotal milestone for the diagnostic testing paradigm.
  • EUA was based on a clinical validation study showing that T-Detect COVID demonstrated sensitivity of 97.1% from date of diagnosis using RT-PCR.
  • This is the first commercially available T-cell test that confirms recent or prior SARS-CoV-2 infections in people.

Co-Diagnostics New Rapid PCR Point-of-Care and at Home Testing Platform to Detect Covid-19 and Other Diseases Using CoPrimer™ Technology

Retrieved on: 
Tuesday, March 2, 2021

The platform chemistry was created by Co-Diagnostics utilizing proprietary CoPrimer technology, Direct Saliva extraction-free protocols, and freeze-dried reagents.

Key Points: 
  • The platform chemistry was created by Co-Diagnostics utilizing proprietary CoPrimer technology, Direct Saliva extraction-free protocols, and freeze-dried reagents.
  • With this platform, Co-Diagnostics plans to revolutionize the availability of accurate, fast and economical PCR tests as regular Covid-19 testing becomes part of the long-term protocol for many organizations.
  • The rapid gold-standard PCR results from this testing platform would be differentiated from less accurate antigen tests.
  • In addition, PCR may even detect the presence of genetic material of the SARS-CoV-2 virus being carried by vaccinated patients.

Sunquest Lauded by Frost & Sullivan for Driving Efficiency and Compliance with Its Differentiated Molecular Laboratory Information Management System

Retrieved on: 
Tuesday, March 2, 2021

Sunquest's comprehensive portfolio of products and services improves operational efficiency, enhances patient care, and lowers healthcare organizations' costs across the spectrum.

Key Points: 
  • Sunquest's comprehensive portfolio of products and services improves operational efficiency, enhances patient care, and lowers healthcare organizations' costs across the spectrum.
  • Sunquest Mitogen supports multiple molecular workflows such as polymerase chain reaction (PCR), reverse transcription-polymerase chain reaction (RT-PCR), next-generation sequencing (NGS), chromosomal microarray (CMA), and mass spectrometry.
  • While other existing LIMS products are compatible with only about two workflows, Sunquest Mitogen supports more than 10 workflows.
  • "Sunquest strategically leverages its sister company, Data Innovations, vast collection of instrument drivers to makeSunquest Mitogen LIMS instrument-agnostic.

Sunquest Lauded by Frost & Sullivan for Driving Efficiency and Compliance with Its Differentiated Molecular Laboratory Information Management System

Retrieved on: 
Tuesday, March 2, 2021

Sunquest's comprehensive portfolio of products and services improves operational efficiency, enhances patient care, and lowers healthcare organizations' costs across the spectrum.

Key Points: 
  • Sunquest's comprehensive portfolio of products and services improves operational efficiency, enhances patient care, and lowers healthcare organizations' costs across the spectrum.
  • Sunquest Mitogen supports multiple molecular workflows such as polymerase chain reaction (PCR), reverse transcription-polymerase chain reaction (RT-PCR), next-generation sequencing (NGS), chromosomal microarray (CMA), and mass spectrometry.
  • While other existing LIMS products are compatible with only about two workflows, Sunquest Mitogen supports more than 10 workflows.
  • "Sunquest strategically leverages its sister company, Data Innovations, vast collection of instrument drivers to makeSunquest Mitogen LIMS instrument-agnostic.

FDA Grants Emergency Use Authorization for Home Collection Kit for Advanta Dx SARS-CoV-2 RT-PCR Assay

Retrieved on: 
Monday, March 1, 2021

The kit is authorized for at-home self-collection by prescription only for individuals suspected of COVID-19 by their health care providers.

Key Points: 
  • The kit is authorized for at-home self-collection by prescription only for individuals suspected of COVID-19 by their health care providers.
  • The assay does not require collection via invasive nasopharyngeal swab, and the companys submission to the FDA demonstrated 100 percent agreement between saliva results from the Advanta Dx Assay and results from paired nasopharyngeal samples tested with authorized assays.
  • Fluidigm continually conducts in silico analyses to determine the effectiveness of the Advanta Dx Assay design to detect SARS-CoV-2.
  • The Advanta Dx SARS-CoV-2 RT-PCR Assay is only for use under the Food and Drug Administrations Emergency Use Authorization.

Co-Diagnostics, Inc. Partner to Offer At-Home Saliva Collection Kits for CoPrimer™-Based COVID-19 PCR Test Through Walgreens Find Care®

Retrieved on: 
Thursday, February 25, 2021

Co-Diagnostics is proud that our technology will be available on an even more widespread basis.

Key Points: 
  • Co-Diagnostics is proud that our technology will be available on an even more widespread basis.
  • Saliva samples sent to CRL are tested with its saliva-based COVID-19 RT-PCR test, which functions via patented CoPrimer probes and primers developed by Co-Diagnostics to detect SARS-CoV-2 (the virus that causes COVID-19) viral RNA.
  • Similar to other tests with FDA EUAs currently in the market, this test has not been formally FDA cleared or approved.
  • Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets a new, state-of-the-art diagnostics technology.

BrainChip Inc. and NaNose Medical Successfully Detect COVID-19 in Exhaled Breath with Fast High-Accuracy Results

Retrieved on: 
Wednesday, February 24, 2021

NaNose Medical is currently collecting samples from three primary worldwide locations and will work with BrainChip to evaluate the data.

Key Points: 
  • NaNose Medical is currently collecting samples from three primary worldwide locations and will work with BrainChip to evaluate the data.
  • A study in China confirmed that breath sensor data is more accurate than the reverse transcription polymerase chain reaction (RT-PCR) test typically used.
  • Accurate testing is key at early stages, even before symptoms manifest, and after treatment before patients are discharged into their communities.
  • Akida is designed to provide a complete ultra-low power and fast AI Edge Network for vision, audio, olfactory and smart transducer applications.

Clinical Reference Laboratory Makes First At-Home COVID-19 Saliva Test Available Through Walgreens Find Care®

Retrieved on: 
Wednesday, February 24, 2021

DEERFIELD, Ill.and LENEXA, Kan., Feb. 24, 2021 /PRNewswire/ -- Clinical Reference Laboratory (CRL), one of the largest privately held clinical testing laboratories in the U.S., and Walgreens today announced that the FDA-authorized CRL Rapid Response COVID-19 Saliva Test is now available through Walgreens Find Care , a digital health platform available on the Walgreens app and Walgreens.com.

Key Points: 
  • DEERFIELD, Ill.and LENEXA, Kan., Feb. 24, 2021 /PRNewswire/ -- Clinical Reference Laboratory (CRL), one of the largest privately held clinical testing laboratories in the U.S., and Walgreens today announced that the FDA-authorized CRL Rapid Response COVID-19 Saliva Test is now available through Walgreens Find Care , a digital health platform available on the Walgreens app and Walgreens.com.
  • "Testing continues to be a critical tool to keep Americans safe even as the vaccine rolls out," said Robert Thompson, CEO at Clinical Reference Laboratory.
  • "The HealthConfirm-branded COVID-19 Saliva Test uses Clinical Reference Laboratory's PCR testing technology, which demonstrated highly accurate results with 100 percent sensitivity and specificity in its FDA EUA filing.
  • Clinical Reference Laboratory received FDAEmergency Use Authorization (EUA) for its saliva-based COVID-19 RT-PCR test in July 2020.

Eurofins Launches New Ultra-Fast Extraction-Free RT-PCR Method and Upgrades its RT-PCR Assay for Use with Pharynx Gargle and Saliva Sample Matrices

Retrieved on: 
Tuesday, February 16, 2021

More than ever, there is a critical need for rapid molecular solutions to increase testing capacity, and provide accurate and faster results.

Key Points: 
  • More than ever, there is a critical need for rapid molecular solutions to increase testing capacity, and provide accurate and faster results.
  • The GSD NovaPrime SARS-CoV-2 Direct RT-PCR is CE marked and has been validated as an extraction-free method.
  • The GSD NovaPrime SARS-CoV-2 (COVID-19) has now been successfully validated for pharynx gargle and saliva samples.
  • These new matrices constitute an easy-to-use sampling method that is particularly useful for self-sampling applications and are suitable for children.